Oxford Promotes Fambrough

Oxford Bioscience Partners has promoted Douglas Fambrough to the position of general partner. He joined the firm in January 2000 as an associate, after having been a genomic scientist with what is now known as the Broad Institute. He led Oxford's deal for Sirna Therapeutics (acquired by Merck for $1.1b), and also was involved with Solexa (sold to Illumina for $550m). www.oxbio.com